Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DARC MATTER

Financiado

Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcr...

Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic Recurrence Tumours evolve, transforming from early-stage curable disease into treatment-refractory, deadly cancer. Therapy resistance is arguably the biggest problem in oncology today, and much of it remains unexplained. The central hypoth... ver más

28/02/2029

FONDAZIONE HUMAN T...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FONDAZIONE HUMAN TECHNOPOLE No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-29

ERC-2023-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

FONDAZIONE HUMAN TECHNOPOLE

2.00M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CANPLAST Cancer cell plasticity on targeted therapy 2M€ Cerrado

EpiCancer Comprehensive Platform for the Functional Characterization o... 2M€ Cerrado

PID2019-111133RB-I00 VARIABILIDAD FENOTIPICA: ORIGENES Y CONSECUENCIA 169K€ Cerrado

Tx-phylogeography High throughput phylogeography of tumors: how the tissue en... 2M€ Cerrado

PID2021-125282OB-I00 USO DE APROXIMACIONES DE CELULA UNICA PARA DECIFRAR LA EPIGE... 472K€ Cerrado

SAF2017-86327-R DESCIFRANDO NUEVAS FUNCIONES DE CAMBIOS EPIGENETICOS INDUCID... Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2024-01-29
Fecha Fin: 2029-02-28

Líder del proyecto

FONDAZIONE HUMAN TECHNOPOLE No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Descripción del proyecto Tumours evolve, transforming from early-stage curable disease into treatment-refractory, deadly cancer. Therapy resistance is arguably the biggest problem in oncology today, and much of it remains unexplained. The central hypothesis of this proposal is that a large proportion of unexplained drug resistance is due to heritable epigenetic alterations, and non-heritable transcriptional plasticity in cancer cells. I refer to these mechanisms as the dark matter of cancer evolution. Genetic, epigenetic and transcriptional adaptation, together with changes in the tumour microenvironment, may happen at the same time in the same tumour. Lack of knowledge of these mechanisms hinders the development of new treatments strategies. Tackling drug resistance requires a unique combination of clinical cohorts, experimental models, evolutionary biology and computational methods. I will map and quantify the mechanisms and evolutionary dynamics of genetic and non-genetic drug resistance at unprecedented scale. I will focus on colorectal cancer, the third most common cancer and second leading cause of cancer-related death worldwide. I will use patient-derived organoid models, matched to clinical cohorts followed longitudinally. I will measure organoid evolution under the pressure of cancer drugs, with and without the tumour microenvironment. I will track cell lineages with lentiviral barcoding and perform longitudinal single cell multi-omics, measuring genomes, epigenomes and transcriptomes of the same cell. I will interpret the results within a unique computational framework that brings together evolutionary theory with machine learning to measure, predict and control resistance. This project will identify new mechanisms and dynamics of cancer drug resistance, deliver new predictive models, and find novel collateral drug sensitivities. This will allow designing rational drug combinations and schedules that will prevent or delay resistance, drastically improving patient outcome.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores